Tagged: Open Access

Oncotarget’s Top 10 Most-Viewed Papers in 2021

Read the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021.

Oncotarget's top 10 papers of 2021

Listen to an audio version of this post

#10: Metformin and berberine, two versatile drugs in treatment of common metabolic diseases

Authors: Haoran Wang, Chen Zhu, Ying Ying, Lingyu Luo, Deqiang Huang, and Zhijun Luo

Institutions: The First Hospital of Nanchang University, Nanchang University and Boston University School of Medicine

Quote: “Metformin has been used as a glucose lowering drug for several centuries and is now a first-line drug for type 2 diabetes mellitus (T2DM). Since the discovery that it activates AMP-activated protein kinase (AMPK) and reduces risk of cancer, metformin has drawn great attentions. Another drug, berberine, extracted from berberis vulgaris L. (root), was an ancient herbal medicine in treating diarrhea.”

#9: Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects

Author: Yuri Lazebnik

Institution: Lerna Consulting

Quote: “A distinctive feature of the SARS-CoV-2 spike protein is its ability to efficiently fuse cells, thus producing syncytia found in COVID-19 patients. This commentary proposes how this ability enables spike to cause COVID-19 complications as well as side effects of COVID-19 vaccines, and suggests how these effects can be prevented.”

#8: Physical activity and telomere length: Impact of aging and potential mechanisms of action

Authors: Nicole C. Arsenis, Tongjian You, Elisa F. Ogawa, Grant M. Tinsley, and Li Zuo

Institutions: University of Massachusetts Boston, Texas Tech University and The Ohio State University College of Medicine

Quote: “Based on the significance of telomere length in aging and the need to understand the potential association with physical activity, the purpose of this systematic review is to investigate whether physical activity and exercise influence telomere length and to discuss possible mechanisms of action.”

#7: Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer

Authors: Jayati Chakrabarti, Loryn Holokai, LiJyun Syu, Nina G. Steele, Julie Chang, Jiang Wang, Syed Ahmed, Andrzej Dlugosz, and Yana Zavros

Institutions: University of Cincinnati, University of Cincinnati College of Medicine, University of Cincinnati Cancer Institute, University of Michigan

Quote: “Tumor cells expressing programmed cell death ligand 1 (PD-L1) interact with PD-1 on CD8+ cytotoxic T lymphocytes (CTLs) to inhibit CTL effector function. In gastric cancer, the mechanism regulating PD-L1 is unclear. The Hedgehog (Hh) signaling pathway is reactivated in various cancers including gastric. Here we tested the hypothesis that Hh-induced PD-L1 inactivates effector T cell function and allows gastric cancer cell proliferation.”

#6: cGAS-STING pathway in oncogenesis and cancer therapeutics

Authors: Brandon Yi Da Hoong, Yunn Hwen Gan, Haiyan Liu, and Ee Sin Chen

Institutions: National University of Singapore and National University Health System (NUHS) Singapore

Quote: “The host innate immunity offers the first line of defense against infection. However, recent evidence shows that the host innate immunity is also critical in sensing the presence of cytoplasmic DNA derived from genomic instability events, such as DNA damage and defective cell cycle progression. This is achieved through the cyclic GMP-AMP synthase (cGAS)/Stimulator of interferon (IFN) genes (STING) pathway. Here we discuss recent insights into the regulation of this pathway in cancer immunosurveillance, and the downstream signaling cascades that coordinate immune cell recruitment to the tumor microenvironment to destroy transformed cells through cellular senescence or cell death programs.”

#5: Anti-aging: senolytics or gerostatics (unconventional view)

Author: Mikhail V. Blagosklonny

Institution: Roswell Park Cancer Institute

Quote: “Based on lessons of cancer therapy, here I suggest how to exploit oncogene-addiction and to combine drugs to achieve selectivity. However, even if selective senolytic combinations will be developed, there is little evidence that a few senescent cells are responsible for organismal aging. I also discuss gerostatics, such as rapamycin and other rapalogs, pan-mTOR inhibitors, dual PI3K/mTOR inhibitors, which inhibit growth- and aging-promoting pathways.”

#4: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment

Authors: Gennady M. Zharinov, Oleg A. Bogomolov, Irina V. Chepurnaya, Natalia Yu. Neklasova, and Vladimir N. Anisimov

Institutions: N.N. Petrov National Medical Research Center of Oncology

Quote: “The antitumor and immunomodulating activities of melatonin are widely known. These activities are based upon the multifactorial mechanism of action on various links of carcinogenesis. In the present paper, the long-term results of the clinical use of melatonin in the combined treatment of patients with prostate cancer of various risk groups were evaluated.”

#3: Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer

Authors: Ayumu Asai, Masamitsu Konno, Miyuki Ozaki, Koichi Kawamoto, Ryota Chijimatsu, Nobuaki Kondo, Takaaki Hirotsu, and Hideshi Ishii

Institutions: Osaka University and Hirotsu Bio Science Inc.

Quote: “Although early detection and diagnosis are indispensable for improving the prognosis of patients with pancreatic cancer, both have yet to be achieved. Except for pancreatic cancer, other cancers have already been screened through scent tests using animals or microorganisms, including Caenorhabditis elegans.”

#2: Inflammatory responses and inflammation-associated diseases in organs

Authors: Linlin Chen, Huidan Deng, Hengmin Cui, Jing Fang, Zhicai Zuo, Junliang Deng, Yinglun, Xun Wang, and Ling Zhao

Institution: Sichuan Agricultural University

Quote: “Here, we review inflammatory responses within organs, focusing on the etiology of inflammation, inflammatory response mechanisms, resolution of inflammation, and organ-specific inflammatory responses.”

#1: The goal of geroscience is life extension

Author: Mikhail V. Blagosklonny

Institution: Roswell Park Cancer Institute

Quote: “Although numerous drugs seemingly extend healthspan in mice, only a few extend lifespan in mice and only one does it consistently. Some of them, alone or in combination, can be used in humans, without further clinical trials.”

Click here to read the latest papers published by Oncotarget in Volume 13.

ONCOTARGET VIDEOS: YouTube | LabTube | Oncotarget.com

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact media@impactjournals.com.

Scientific Integrity

Open-Access Oncotarget Shifts to Continuous Publishing

As of 2022, the peer-reviewed and open-access journal Oncotarget has shifted to continuous publishing.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form.
Listen to an audio version of this announcement

BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget has operated as a traditional-style journal that publishes online page numbered issues of peer-reviewed papers. Final paginated issues were then released in their permanent form to Pubmed.

As of 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form. This means that qualified, rigorously peer-reviewed articles will be published online as soon as they are in their fully formatted and final version of record. With continuous publication, articles posted online are complete with citation details and are available in full text html and PDF formats. Additionally, research papers will appear on PubMed quickly—just days after the papers are published by Oncotarget.

Why the change? In an increasingly digital world, the open-access continuous publishing model is ideal for authors, researchers and overall readership. Continuous publishing allows for faster research dissemination, citation and clinical application, compared to a traditional format.

Oncotarget is committed to doing our part to ensure that research is available to the biomedical community as quickly as possible, while maintaining high standards of quality.

To learn more about Oncotarget, visit Oncotarget.com or connect with us on social media:

About Impact Journals (Oncotarget’s publisher):

Impact Journals is a New York-based open-access publisher with a mission to provide scientists with the opportunity to share their exceptional discoveries, and to present vital findings from different fields of biomedical science. Our goal is life without disease.

For media inquiries, please contact media@impactjournals.com.

Captain of Team Open Access Rides Again for Cancer Research

For the past four summers, Impact Journals has sponsored Team Open Access in the Ride for Roswell. The peloton has been captained by Sergei Kurenov, who is the Director of Surgical Simulation at Roswell Park Comprehensive Cancer Center — one of the leading cancer treatment and research centers in the nation. This year, Team Open Access was one of the many teams that participated to raise more than $5 million to help find a cure for cancer.

Prior to the 2021 Ride for Roswell (#RFR21) on August 7, we asked Sergei for his thoughts on the experience and motivation for riding. 

Please tell us how you got started in the Ride for Roswell event and what pushes you to participate each year. 

Kurenov: When I started working at Roswell Park Comprehensive Cancer Center, I saw how enthusiastically people supported this event and made a lot of contributions of their time in fundraising, patient care support, and cancer research. I wanted to be a part of this community. 

This will be your fourth year as team captain and sixth year participating in the Ride for Roswell. What has been your most memorable year or moment since you’ve started?

Kurenov: My first year of the Ride is the most memorable. More than a few thousand riders performed the National Anthem. Then, all the riders cheered on the cancer survivors, reminding us of exactly why we participate.

During last year’s Summer of the Ride, you were a part of over 600 teams that rode to raise more than $3.6 million in the fight against cancer amid a global pandemic. Looking back, how has that specific Ride impacted your outlook on this year’s event and cancer research?

Kurenov: The pandemic has highly affected cancer research. Physicians and researchers are working very hard to minimize pandemic impact and get life back to normal for our patients.

This year, we already raised [more than] $5 million, which will be provided to the development of cancer treatments and cancer research.

Sponsored by Impact Journals, Team Open Access is once again captained by Sergei Kurenov who explains his motivation to participate in the Ride for Roswell.
(Photo Courtesy of Roswell Park Comprehensive Cancer Center)

Tell us a little bit about the 2021 Open Access team.

Kurenov: The 2021 Open Access team has grown again and now we have nine team members, ranging in ages from 13 to 65. Most of the members are scientists in the cancer research field. 

Who is the fastest team member? The longest tenured teammate of yours? And, why do you think you make the perfect captain for this team?

Kurenov: Andrei is a great rider and I believe he is the fastest team member.

Liliya and Elena are the longest-tenured teammates for the last six years. They provide a tremendous help in the fundraising and in team organizing. They are also great photographers, making memorable images during the Ride. Each year, they create special Open Access team t-shirts which we are proud to wear during the Ride.

Who, or what, will you be focusing on as team captain this time around?

Kurenov: This year, Sofia joined the Open Access team. She is 13 years old and wants to ride 10 miles. Sofia and the rest of our team will ride together. Perhaps I will join the team or will have a barbecue for the whole team to celebrate afterwards.

How do you generally celebrate following the Ride?

Kurenov: After the Ride, all team members and many of our friends from Buffalo are planning to join a barbecue party in our backyard. Everyone is very welcome to the party.

Please give us your best pitch for people to start or continue donating to cancer research.

Kurenov: Earlier this year, I lost a very close friend who had fought against cancer for the last 17 years. When he was diagnosed, doctors predicted around 10 years of his survival after the initial treatment. However, thanks to the cancer research and new treatment developments in oncology, he almost doubled the doctors’ predictions. And, until this year, he lived a full life, working on cancer research, organizing scientific conferences, traveling around the world and making great photographs. His example shows that the constant cancer research and new technologies can help oncological patients. So, please continue donating to cancer research. This certainly will help to cure cancer more efficiently and save more lives.

Just like we requested of you last year, give us your best pitch for folks to join Team Open Access in 2022.

Kurenov: I am proud to announce that our team is supported again by Impact Journals – which publishes open-source, cancer-related scientific journals OncotargetAgingGenes & Cancer and Oncoscience. These journals include high-impact research papers of general interest and biological significance in all fields of cancer research. As an example, I would like to mention the studies published by Impact Journals that cycling is linked to a substantial decrease in the risk of developing and dying from cancer or heart disease. 

Join our team and help us reach our goal or donate to our efforts! No matter how you choose to support us, YOU are making a difference in the lives of the thousands of patients who turn to Roswell Park Comprehensive Cancer Center for hope each year.

Click here to learn more about the Ride for Roswell.

YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact media@impactjournals.com.

The Ride for Roswell: Rolling Around The Track August 7

Listen to an audio version of this article

The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—with ambitious goals to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 25 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure.

When it opened its doors in Buffalo in 1898, Roswell Park Comprehensive Cancer Center was the first cancer research-focused institution in the world. Today, this institution is one of only four National Cancer Institute-designated comprehensive cancer centers in the state of New York. Roswell Park Comprehensive Cancer Center is ranked by U.S. News & World Report as one of the best cancer hospitals in the United States.

The Origin of The Ride

The Ride for Roswell started in 1989, when Mitch Flynn, owner of the advertising agency Flynn & Friends, met Katherine Gioia. Katherine was a four-year-old patient battling a rare form of cancer. After Katherine’s death, less than a year after her diagnosis, Katherine’s mother, Anne Gioia, and aunt, Donna Gioia, founded the Roswell Park Alliance Foundation in her memory to raise money for cancer research and treatment. On June 29, 1996, Mitch and Alliance Foundation staff launched the first Ride for Roswell.

In the 25 years since then, thanks to many thousands of riders and generous donations, the Ride for Roswell has raised over $60 million to fund cancer research. The event has become one of the largest single-day charity rides in the United States. 

This Year

Traditionally (excluding last year’s COVID-19 inspired “Summer of The Ride”), teams of bicyclists register to ride in a one-day event and raise money to support their participation. This summer, there are two ways to ride. Riders can join in-person at various locations (socially distanced) throughout the Western New York area on Saturday, August 7, 2021. Participants can also ride on their own throughout the month of August.

Impact Journals has been sponsoring the Ride for Roswell since 2018. The Impact Journals peloton, Team Open Access (named after the open-source online medical journals OncotargetAgingGenes & Cancer, and Oncoscience), is captained by Sergei Kurenov. Sergei (who has been riding in the event since 2016) works at the Roswell Park Comprehensive Cancer Center to create, develop, and implement innovative diagnostic and surgical pre-planning software used in cancer treatment.

“Roswell Park Comprehensive Cancer Center is dedicated to providing a high level of care for cancer patients,” Sergei said. “By contributing to the Ride for Roswell, we are helping our patients to fight this most dangerous disease.”

Join Us!

There is still time to join Team Open Access and the Ride for Roswell this summer. You can also support the team by giving a donation of any size. Any avenue of support you may choose to donate to the Ride for Roswell will make a difference and change lives. 

“Finding a cure for cancer is something we are all incredibly passionate about, and we are so thankful and grateful for your support,” Sergei said. “Together, we can make a difference!”

Visit our team page to join or donate today.

Click here to learn more about the Ride for Roswell.

YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube

For media inquiries, please contact media@impactjournals.com.

2021 Ride for Roswell
2021 Ride for Roswell